4D Molecular director discloses 11,250-share option

4D Molecular Therapeutics director Glenn Sblendorio reported initial beneficial ownership of a stock option covering 11,250 shares of the company’s common stock at an exercise price of $2.76 per share.

Rhea-AI Filing Summary

4D Molecular Therapeutics director Glenn Sblendorio reported initial beneficial ownership of a stock option covering 11,250 shares of the company’s common stock at an exercise price of $2.76 per share. The option was granted on April 9, 2025 and vests over three years: one-third of the shares vest on the first anniversary of that date, with the remaining two-thirds vesting in equal monthly installments over the following two years, so that all 11,250 shares are fully vested and exercisable on the third anniversary.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SBLENDORIO GLENN

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 11,250 contracts (Direct)

Footnotes (1)

1. F1. One-third of the shares subject to the option vest on the first anniversary measured from April 9, 2025 (the "Vesting Commencement Date"), and 1/36th of the total number of shares vest in twenty-four (24) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Glenn Sblendorio report on his Form 3 for FDMT?

He reported beneficial ownership of a stock option (right to buy) for 11,250 shares of 4D Molecular Therapeutics common stock at an exercise price of $2.76 per share.

What is Glenn Sblendorio’s role at 4D Molecular Therapeutics (FDMT)?

The filing identifies Glenn Sblendorio as a director of 4D Molecular Therapeutics, Inc.

How many shares underlie Glenn Sblendorio’s reported stock option at FDMT?

The stock option gives the right to purchase 11,250 shares of 4D Molecular Therapeutics common stock.

What is the vesting schedule of Glenn Sblendorio’s FDMT stock option?

One-third of the option vests on the first anniversary of April 9, 2025, and the remaining shares vest in 24 equal monthly installments, so all shares are vested by the third anniversary.

Is the 11,250-share stock option held directly or indirectly by Glenn Sblendorio?

The Form 3 indicates the option is held with direct (D) ownership.

Does this FDMT Form 3 show any stock being bought or sold?

No purchases or sales are shown; the Form 3 reflects beneficial ownership of a stock option and its vesting terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/07/2026 - 09:10 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SBLENDORIO GLENN

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/05/2026

3. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	04/08/2035	Common Stock	11,250	$2.76	D

Explanation of Responses:

1. One-third of the shares subject to the option vest on the first anniversary measured from April 9, 2025 (the "Vesting Commencement Date"), and 1/36th of the total number of shares vest in twenty-four (24) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.

	/s/ Scott Bizily as Attorney-in-Fact for Glenn Sblendorio	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.